HALO vs. HROW

In the year-to-date period, HALO achieves a 23.51% return, which is significantly lower than HROW's 248.30% return. Over the past 10 years, HALO has outperformed HROW with an annualized return of 18.23%, while HROW has yielded a comparatively lower 16.25% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Harrow Health, Inc. (HROW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current HALO Sharpe Ratio is 0.39, which is lower than the HROW Sharpe Ratio of 4.47. The chart below compares the historical Sharpe Ratios of HALO and HROW, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither HALO nor HROW has paid dividends to shareholders.

The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum HROW drawdown of -99.46%. Use the drawdown chart below to compare losses from any high point for HALO and HROW. For additional features, visit the drawdowns tool.

The current volatility for Halozyme Therapeutics, Inc. (HALO) is 23.84%, while Harrow Health, Inc. (HROW) has a volatility of 25.40%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than HROW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Harrow Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.